Search Results - Niven Mehra

Refine Results
  1. 1

    Reply to Birhan Demirhan, Aysenur Elmali, and Cem Onal’s Letter to the Editor re: Daniela E. Oprea-Lagera, Tessa van Elst, Shafak Aluwini, et al. How Does Routine Prostate-specific... by Daniela Oprea-Lager, Tessa van Elst, Shafak Aluwini, Herman Stoevelaar, Niven Mehra

    Published in European Urology Open Science (2025-11-01)
    Get full text
    Article


  2. 2

    LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma by Sandra van Wilpe, Sofie H. Tolmeijer, I. Jolanda M. de Vries, Rutger H. T. Koornstra, Niven Mehra

    Published in Immuno (2021-04-01)
    Get full text
    Article


  3. 3

    Bone marrow dosimetry in low volume mHSPC patients receiving Lu-177-PSMA therapy using SPECT/CT by Dagmar Grob, Bastiaan M. Privé, Constantijn H. J. Muselaers, Niven Mehra, James Nagarajah, Mark W. Konijnenberg, Steffie M. B. Peters

    Published in EJNMMI Physics (2024-04-01)
    Get full text
    Article


  4. 4

    172 Cancer immunotherapy response monitoring with whole blood immuno-transcriptomic profiling by Pedro Romero, Niven Mehra, Laura Ciarloni, Noushin Hadadi, Rutger Koornstra, Sandra van Wilpe, Eric Durandau, Sahar Hosseinian Ehrensberger, Sylvain Monnier-Benoit

    Published in Journal for ImmunoTherapy of Cancer (2023-11-01)
    Article


  5. 5

    A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery by Winald R Gerritsen, Johannes Textor, Niven Mehra, Jeroen H A Creemers, W Joost Lesterhuis, Carl G Figdor, I Jolanda M de Vries

    Published in Journal for ImmunoTherapy of Cancer (2021-05-01)
    Get full text
    Article


  6. 6

    Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysis by Catharina J. P. Op ’t Hoog, Sabien J. E. Bosman, Emmy Boerrigter, Niven Mehra, Inge M. van Oort, Nielka P. van Erp, Wietske Kievit

    Published in Therapeutic Advances in Medical Oncology (2024-12-01)
    Get full text
    Article


  7. 7

    Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the ‘trials within cohorts’ study ProBCI by Lambertus A Kiemeney, Anke Richters, Richard P Meijer, Niven Mehra, Joost L Boormans, Antoine G van der Heijden, Michiel S van der Heijden, Katja K Aben

    Published in BMJ Open (2021-05-01)
    Get full text
    Article


  8. 8

    The Androgen Regulated lncRNA <i>NAALADL2-AS2</i> Promotes Tumor Cell Survival in Prostate Cancer by Levi Groen, Viktor Yurevych, Harshitha Ramu, Johnny Chen, Lianne Steenge, Sabrina Boer, Renske Kuiper, Frank P. Smit, Gerald W. Verhaegh, Niven Mehra, Jack A. Schalken

    Published in Non-Coding RNA (2022-12-01)
    Get full text
    Article


  9. 9

    Anti-neoplastic effects of the antipsychotic drug penfluridol in preclinical prostate cancer models by Arjanneke F. van de Merbel, Maaike H. van der Mark, Tilly Aalders, Martin Puhr, Niven Mehra, Jack Schalken, Geertje van der Horst, Gabri van der Pluijm

    Published in Frontiers in Oncology (2025-10-01)
    Get full text
    Article


  10. 10

    Whole genome sequencing of 378 prostate cancer metastases reveals tissue selectivity for mismatch deficiency with potential therapeutic implications by Daniel J. Vis, Sander A. L. Palit, Marie Corradi, Edwin Cuppen, Niven Mehra, Martijn P. Lolkema, Lodewyk F. A. Wessels, Michiel S. van der Heijden, Wilbert Zwart, Andries M. Bergman

    Published in Genome Medicine (2025-03-01)
    Get full text
    Article


  11. 11

    Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-labe... by Mark R Middleton, Winald R Gerritsen, Ian Walters, Licia Rivoltini, Niven Mehra, Jeroen H A Creemers, Carl G Figdor, I Jolanda M de Vries, Uzi Gileadi, Inka Pawlitzky, Konstantina Grosios, Petronella B Ottevanger

    Published in BMJ Open (2021-11-01)
    Get full text
    Article


  12. 12

    Treatment Patterns and Use of Immune Checkpoint Inhibitors Among Patients with Metastatic Bladder Cancer in a Dutch Nationwide Cohort by Anke Richters, Debbie G.J. Robbrecht, Richard P. Meijer, Antoine G. van der Heijden, Lambertus A.L.M. Kiemeney, Joan van den Bosch, Britt B.M. Suelmann, Berna C. Özdemir, Niven Mehra, Katja K.H. Aben

    Published in European Urology Open Science (2024-01-01)
    Get full text
    Article


  13. 13

    Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration‐resistant prostate cancer undergoing first‐line abirater... by Emmy Boerrigter, Guillemette E. Benoist, Inge M. vanOort, Gerald W. Verhaegh, Onno vanHooij, Levi Groen, Frank Smit, Irma M. Oving, Pieter deMol, Tineke J. Smilde, Diederik M. Somford, Niven Mehra, Jack A. Schalken, Nielka P. vanErp

    Published in Molecular Oncology (2021-09-01)
    Get full text
    Article


  14. 14

    The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer by Tessa van Elst, Niven Mehra, Sjaak Bloem, André N. Vis, Bart P. Wijsman, Daphne Luijendijk-de Bruin, Joyce M. van Dodewaard-de Jong, Pieter L. van den Berg, Jules Lavalaye, Shafak Aluwini, Derya Yakar, Daniela E. Oprea-Lager, Peter F. A. Mulders, Haiko J. Bloemendal, Jean-Paul A. van Basten

    Published in Scientific Reports (2025-04-01)
    Get full text
    Article


  15. 15

    Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancer by Sandra van Wilpe, Davide Croci, Sara S. Fonseca Costa, Iris B.A.W. te Paske, Sofie H. Tolmeijer, Jolique van Ipenburg, Leonie I. Kroeze, Simona Pavan, Sylvain Monnier-Benoit, Guido Coccia, Noushin Hadadi, Irma M. Oving, Tineke J. Smilde, Theo van Voorthuizen, Marieke Berends, Mira D. Franken, Marjolijn J.L. Ligtenberg, Sahar Hosseinian Ehrensberger, Laura Ciarloni, Pedro Romero, Niven Mehra

    Published in JCI Insight (2025-03-01)
    Get full text
    Article


  16. 16

    Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer by Xiaolin Zhu, Tatyanah Farsh, Daniël Vis, Ivan Yu, Haolong Li, Tianyi Liu, Martin Sjöström, Raunak Shrestha, Jeroen Kneppers, Tesa Severson, Meng Zhang, Arian Lundberg, Thaidy Moreno Rodriguez, Alana S. Weinstein, Adam Foye, Niven Mehra, Rahul R. Aggarwal, Andries M. Bergman, Eric J. Small, Nathan A. Lack, Wilbert Zwart, David A. Quigley, Michiel S. van der Heijden, Felix Y. Feng

    Published in The Journal of Clinical Investigation (2024-10-01)
    Get full text
    Article


  17. 17

    Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer by Maud Rijnders, J. Alberto Nakauma-González, Debbie G. J. Robbrecht, Alberto Gil-Jimenez, Hayri E. Balcioglu, Astrid A. M. Oostvogels, Maureen J. B. Aarts, Joost L. Boormans, Paul Hamberg, Michiel S. van der Heijden, Bernadett E. Szabados, Geert J. L. H. van Leenders, Niven Mehra, Jens Voortman, Hans M. Westgeest, Ronald de Wit, Astrid A. M. van der Veldt, Reno Debets, Martijn P. Lolkema

    Published in Nature Communications (2024-02-01)
    Get full text
    Article


  18. 18

    TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment by Sjoerd O Klaver, André N Vis, Gerard Vreugdenhil, Haiko J Bloemendal, Pieter L van den Berg, Niven Mehra, Mathijs P Hendriks, Tessa van Elst, Sjaak Bloem, Zarina Lalmahomed, Daphne Luijendijk, Jean-Paul A van Basten, Roderick CN van den Bergh, Joyce M van Dodewaard-de Jong, Addy CM van de Luijtgaarden, Luc AJ Roelofs, Eric HJEJ Vrijhof, Bart P Wijsman, Peter FA Mulders

    Published in BMJ Open (2023-08-01)
    Get full text
    Article


  19. 19

    PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine by Mariaelena Pierobon, Johann De Bono, Ruth Riisnaes, Giuseppe Giaccone, Matthew Blackburn, Lance Liotta, Vienna Ludovini, Neil J Shah, Giuseppina Improta, Antonella Ravaggi, Niven Mehra, Angelo Sidoni, Elisa Baldelli, K Alex Hodge, Guido Bellezza, Guido Gambara, Martina Mandarano, Chamodya Ruhunusiri, Bryant Dunetz, Maysa Abu-Khalaf, Julia Wulfkuhle, Rosa I Gallagher, Franco Odicino, Maria Isabella Sereni, Angela Zupa, Perry Demsko, Lucio Crino', Emanuel F Petricoin

    Published in Journal for ImmunoTherapy of Cancer (2021-10-01)
    Get full text
    Article


  20. 20

    Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial by Bastiaan M. Privé, Marcel J. R. Janssen, Inge M. van Oort, Constantijn H. J. Muselaers, Marianne A. Jonker, Michel de Groot, Niven Mehra, J. Fred Verzijlbergen, Tom W. J. Scheenen, Patrik Zámecnik, Jelle O. Barentsz, Martin Gotthardt, Walter Noordzij, Wouter V. Vogel, Andries M. Bergman, Henk G. van der Poel, André N. Vis, Daniela E. Oprea-Lager, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah

    Published in BMC Cancer (2020-09-01)
    Get full text
    Article


Search Tools: